Report

The tissue microarray market is expected to register a CAGR of more than 10.3% during the forecast period.

Key Highlights
-The COVID-19 pandemic was an unprecedented health concern and had significantly impacted the tissue microarray market. The pandemic turned a spotlight on the molecular diagnostics industry worldwide, with the rapid development of diagnostics, fast-tracked regulatory clearances, and ramped-up distribution in various regions to help curb the spread of the virus. For instance, as of January 2022, a published article in Karger had reported that tissue microarrays incorporating a total of 879 tissue cores from conjunctival (n = 84), sinonasal (n = 95), and lung (bronchiolar/alveolar; n = 96) specimens were investigated for protein expression by immunohistochemistry. The study confirmed and extended previous findings and contributed to a better understanding of potential SARS-CoV-2 infection sites along the human respiratory tract. Such studies had indicated significant demand for tissue microarray products amid the pandemic. Also, with the introduction of vaccine development and the upliftment of lockdown restrictions, the market was expected to witness positive growth in the coming period.
-The growth of the market can be attributed to factors such as growing research and development in drug discovery, the rising burden of cancer, and increasing demand for accurate diagnostic methods.
-The rising prevalence of cancer is driving the demand for tissue microarray products. For instance, the increasing cancer burden is one of the major factors driving the market. According to the International Agency for Research on Cancer (IARC) 2023, the global incidence of cancer is expected to reach 24.6 million by the year 2030 and 30.2 million by 2040. Furthermore, according to the Cancer Statistics Japan 2023, there were 96,400 prostate cancer cases diagnosed in Japan in 2022, compared to 95,400 in 2021. Thus, the demand for tissue microarrays is increasing in cancer research to analyze the biopsy or tumor samples, thereby anticipated to drive the market growth.
-Additionally, strategic initiatives taken by market players are also propelling the growth of the market. For instance, in March 2021, Oxford BioDynamics Plc and Agilent Technologies signed a supply and resale agreement for the manufacture and sale of the new EpiSwitch Explorer Array Kit. Furthermore, in March 2023, 3DHISTECH, a manufacturer of digital slide scanners, software applications for digital slides, and other products, including tissue microarray machines, and Epredia, a member of the PHC Group (headquartered in Japan) inaugurated a Pathology Innovation Incubator to develop methods and equipment for faster and more precise diagnosis of cancer and tumor lesions. Therefore, the partnership among key players is anticipated to contribute to the market studied due to the increased adoption of microarrays.
-Furthermore, the rising applications of tissue microarray in high throughput screening are anticipated to bolster the market growth. For instance, according to the study published in Scientific Reports in November 2022, tissue microarrays are frequently used for the rapid analysis of large numbers of tissue samples, and the use of tissue microarrays is increasing in spectroscopic analysis, where specific molecular markers are targeted via immunostaining.
-Moreover, with the increase in the spending on research and development, there is increased adoption of tissue microarrays in the testing of drugs and biologics, driving the market growth. For instance, as per the PhRMA in July 2022, during the past 20 years, member companies have spent more than USD 1.1 trillion on the research and development of new medications. Therefore, the rising investments in R&D will lead to increased demand for tissue microarrays in the testing of samples, thereby propelling the market growth.
-However, the availability of alternative technologies and the high cost associated with microarray techniques are the factors hindering market growth.


Tissue Microarray Market Trends

Immunohistochemistry Segment is Expected to Hold a Significant Market Share in the Tissue Microarray Market


- Immunohistochemistry is one of the most common applications of immunostaining. It involves the process of selectively identifying antigens in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues.
- The major factors fueling segment growth are the increasing application of immunohistochemistry in tissue diagnostics and the growing research and development. For instance, as per the study published in February 2022 in Scientific Reports, a novel detection technique for activated Rac/Cdc42 in human cancer FFPE tissues was developed by scientists using a developed rapid immunohistochemistry (R-IHC) device. The device helps in carrying out antigen-antibody reactions that can be facilitated up to 1,200-fold by alternating current-based high-speed micro agitation. Such advantages of microarrays in immunohistochemistry research are expected to drive market growth due to increased adoption.
- Additionally, the launch of new products is also propelling the market's growth due to the increased adoption of biotechnological research. For instance, in March 2021, Roche launched the DISCOVERY Green HRP kit. It is the newest addition to the comprehensive collection of modular-based detection kits to identify and profile biomarkers and cell populations in tissue-based research. The DISCOVERY Green HRP (horseradish peroxidase) kit can be used in combination with other detection kits, expanding the multiplexing capability of both immunohistochemistry (IHC) and in situ hybridization (ISH) by providing a distinct color that contrasts with other chromogens.
- Thus, due to the rising initiatives from the key market players and increasing applications of immunohistochemistry, the market is expected to witness significant growth over the forecast period.


North America is Expected to Hold a Significant Share in the Market Over the Forecast Period


- In North America, the United States has held a major share of the market. The major factors contributing to the market growth are the presence of many market players engaged in manufacturing and expanding the portfolio of instruments and reagents for molecular diagnostic testing. The region also witnesses the presence of well-established healthcare diagnostic facilities.
- According to the American Cancer Society 2023, 1.9 million new cancer cases are expected to be diagnosed in the United States in 2023. Furthermore, according to the Government of Canada, in June 2022, an estimated 233,900 people in Canada will be diagnosed with cancer 2022. Such a huge incidence of cancers in North America is therefore expected to drive market growth in this region due to the increased adoption of tissue microarray for cancer research in the region.
- Strategic initiatives adopted by the key market players are anticipated to drive market growth. For instance, in January 2022, Histobiolab, a division of Creative Bioarray, reported that it had developed a professional tissue microarray to meet precise research needs. In addition, in July 2021, BioIVT acquired Tissue Solutions Ltd, a provider of high-quality human tissue and other biological materials for use in drug discovery, target identification and validation, assay development and validation, and biomarker and companion diagnostic development. Such launches and partnerships in the region helps in reaching out to a large client base, driving the market growth.
- Thus, the factors such as rising incidence of cancers and initiatives adopted by the key market players are expected to witness significant growth over the forecast period.


Tissue Microarray Industry Overview

The tissue microarray market is moderately competitive, with the presence of several global and international market players. The factors owing to the competition include key players adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some players operating in the market are Novus Biologicals, OriGene Technologies, Inc., ProteoGenex, PREMIER Biosoft, and BioIVT, among others.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support